Rebabonye B Pharithi1, Deepti Ranganathan2, Jim O'Brien2, Emmanuel E Egom2, Cathie Burke3, Daniel Ryan3, Christine McAuliffe4, Marguerite Vaughan4, Tara Coughlan3, Edwina Morrissey4, John McHugh5, David Moore2, Ronan Collins6. 1. Department of Cardiology, Adelaide and Meath Hospital, Incorporated with National Children Hospital, Tallaght, Dublin, Ireland. rpharithi@gmail.com. 2. Department of Cardiology, Adelaide and Meath Hospital, Incorporated with National Children Hospital, Tallaght, Dublin, Ireland. 3. Department of Age-Related Healthcare and Stroke Service, Adelaide and Meath Hospital, Incorporated with National Children Hospital, Tallaght, Dublin, Ireland. 4. Department of Pharmacy, Adelaide and Meath Hospital, Incorporated with National Children Hospital, Tallaght, Dublin, Ireland. 5. Department of Haematology, Adelaide and Meath Hospital, Incorporated with National Children Hospital, Tallaght, Dublin, Ireland. 6. Department of Age-Related Healthcare and Stroke Service, Adelaide and Meath Hospital, Incorporated with National Children Hospital, Tallaght, Dublin, Ireland. ronan.collins@amnch.ie.
Abstract
BACKGROUND: Non-vitamin K antagonist oral anticoagulants (NOACs) are a major advance for stroke prevention in atrial fibrillation (AF). Use of the vitamin K antagonist (VKA), warfarin, has dropped 40% since 2010 in our institution. There is limited Irish hospital data on NOAC prescribing for stroke prevention. METHOD: Single centre, retrospective observational cohort study of consecutive AF patients at increased risk of stroke and/or awaiting electrical cardioversion. Data on prescribed NOACs from February 2010 till July 2015 was collected from the electronic inpatient record. Appropriateness of prescriptions was based on CHA2DS2-VASC score and accuracy on individual NOAC SPCs. Potential drug interactions and bleeding risk were also quantified. RESULTS: A total of 348 patients AF and increased risk of stroke (CHA2DS2-VASC score > 1 for men and > 2 for women) were studied. Forty-eight percent were female with a mean age 71 ± 18.6 years, 52% of whom were > 75. Mean CHA2DS2-Vasc and HAS-BLED scores were 4.1 ± 1.8 and 1.4 ± 0.8, respectively. Rivaroxaban, dabigatran and apixaban were prescribed to 154 (54.2%), 106 (34.3%) and 41 (13.2%) patients, respectively. 20.4% had inaccurate prescriptions; 92.9% (n = 65) underdosed and 7.1% (n = 5) on inappropriately higher doses. Neither choice of NOAC, age, history of anaemia, previous bleeding or co-prescribed antiplatelets influenced the accuracy of prescription (p = NS), but decreased renal function appeared to do so (p = 0.05). CONCLUSION: Our study highlights significant inaccuracies in NOAC prescribing. Patients commenced on NOACs should be assessed and followed up in a multidisciplinary AF clinic to ensure safe and effective prescribing and stroke prevention.
BACKGROUND: Non-vitamin K antagonist oral anticoagulants (NOACs) are a major advance for stroke prevention in atrial fibrillation (AF). Use of the vitamin K antagonist (VKA), warfarin, has dropped 40% since 2010 in our institution. There is limited Irish hospital data on NOAC prescribing for stroke prevention. METHOD: Single centre, retrospective observational cohort study of consecutive AFpatients at increased risk of stroke and/or awaiting electrical cardioversion. Data on prescribed NOACs from February 2010 till July 2015 was collected from the electronic inpatient record. Appropriateness of prescriptions was based on CHA2DS2-VASC score and accuracy on individual NOAC SPCs. Potential drug interactions and bleeding risk were also quantified. RESULTS: A total of 348 patientsAF and increased risk of stroke (CHA2DS2-VASC score > 1 for men and > 2 for women) were studied. Forty-eight percent were female with a mean age 71 ± 18.6 years, 52% of whom were > 75. Mean CHA2DS2-Vasc and HAS-BLED scores were 4.1 ± 1.8 and 1.4 ± 0.8, respectively. Rivaroxaban, dabigatran and apixaban were prescribed to 154 (54.2%), 106 (34.3%) and 41 (13.2%) patients, respectively. 20.4% had inaccurate prescriptions; 92.9% (n = 65) underdosed and 7.1% (n = 5) on inappropriately higher doses. Neither choice of NOAC, age, history of anaemia, previous bleeding or co-prescribed antiplatelets influenced the accuracy of prescription (p = NS), but decreased renal function appeared to do so (p = 0.05). CONCLUSION: Our study highlights significant inaccuracies in NOAC prescribing. Patients commenced on NOACs should be assessed and followed up in a multidisciplinary AF clinic to ensure safe and effective prescribing and stroke prevention.
Authors: Anne M Holbrook; Jennifer A Pereira; Renee Labiris; Heather McDonald; James D Douketis; Mark Crowther; Philip S Wells Journal: Arch Intern Med Date: 2005-05-23
Authors: Stefan Knecht; Christian Oelschläger; Thomas Duning; Hubertus Lohmann; Johannes Albers; Christoph Stehling; Walter Heindel; Günter Breithardt; Klaus Berger; E Bernd Ringelstein; Paulus Kirchhof; Heike Wersching Journal: Eur Heart J Date: 2008-07-29 Impact factor: 29.983
Authors: Stuart J Connolly; Michael D Ezekowitz; Salim Yusuf; John Eikelboom; Jonas Oldgren; Amit Parekh; Janice Pogue; Paul A Reilly; Ellison Themeles; Jeanne Varrone; Susan Wang; Marco Alings; Denis Xavier; Jun Zhu; Rafael Diaz; Basil S Lewis; Harald Darius; Hans-Christoph Diener; Campbell D Joyner; Lars Wallentin Journal: N Engl J Med Date: 2009-08-30 Impact factor: 91.245
Authors: Paulus Kirchhof; Angelo Auricchio; Jeroen Bax; Harry Crijns; John Camm; Hans-Christoph Diener; Andreas Goette; Gerd Hindricks; Stefan Hohnloser; Lukas Kappenberger; Karl-Heinz Kuck; Gregory Y H Lip; Bertil Olsson; Thomas Meinertz; Silvia Priori; Ursula Ravens; Gerhard Steinbeck; Elisabeth Svernhage; Jan Tijssen; Alphons Vincent; Günter Breithardt Journal: Eur Heart J Date: 2007-09-25 Impact factor: 29.983
Authors: Ulrika Gillespie; Anna Alassaad; Dan Henrohn; Hans Garmo; Margareta Hammarlund-Udenaes; Henrik Toss; Asa Kettis-Lindblad; Håkan Melhus; Claes Mörlin Journal: Arch Intern Med Date: 2009-05-11
Authors: Michael Nabauer; Andrea Gerth; Tobias Limbourg; Steffen Schneider; Michael Oeff; Paulus Kirchhof; Andreas Goette; Thorsten Lewalter; Ursula Ravens; Thomas Meinertz; Günter Breithardt; Gerhard Steinbeck Journal: Europace Date: 2009-01-18 Impact factor: 5.214
Authors: Abdulrhman Al Rowily; Zahraa Jalal; Malcolm J Price; Mohammed H Abutaleb; Hind Almodiaemgh; Maha Al Ammari; Vibhu Paudyal Journal: Eur J Clin Pharmacol Date: 2021-12-22 Impact factor: 2.953